PPD and SNBL Announce Japanese Clinical Development Joint Venture and Additional Collaborations
PPD and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture.
Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. (SNBL) (TSE:2395) today announced an agreement to form a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.
The joint venture, to be named PPD-SNBL, will result from the combination of SNBL’s clinical research division and PPD’s clinical development operations in Japan, and it will have offices in Tokyo, Osaka and Kagoshima with approximately 400 clinical development professionals. This combination brings together PPD’s global clinical trial expertise with SNBL’s nearly 20-year history of providing clinical development services for biopharmaceutical companies in Japan.
Under the terms of the agreement, PPD-SNBL will be majority owned by PPD. Ryoichi Nagata M.D., Ph.D., chairman and president of SNBL, will serve as the president of the joint venture. The parties have also entered into an agreement under which they will collaborate in a number of areas outside of the clinical development joint venture in Japan. This collaboration will involve SNBL’s early stage businesses (including translational research out-licensing business), Phase I services in the United States for Japanese bridging studies, specialized neuroscience studies, vaccines studies and biologic studies, Phase I services in Japan, Japanese bioanalysis services and site management services in Japan.
“PPD is honored to be joining forces with SNBL to provide a unique clinical development service offering in Japan for biopharmaceutical clients,” said David Simmons, chairman and CEO of PPD. “PPD-SNBL will be one of the largest clinical development service providers in Japan, both for clients seeking to conduct global clinical trials and also for trials based solely in Japan, and builds on the shared commitment of both organizations to the delivery of high-quality clinical development services.”
Dr. Nagata said, “The close partnership between SNBL and PPD offers significant opportunities to promote and strengthen global clinical trials in Japan. In addition, the formation of this joint venture would also assist in completing our plan of building a strong global value chain in the entire drug development process.”
The transactions are subject to customary closing conditions and are expected to close in April 2015.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
